×
About 1,650 results

ALLMedicine™ Trichomoniasis Center

Research & Reviews  421 results

Facilitators and barriers to point-of-care testing for sexually transmitted infections ...
https://doi.org/10.1186/s12879-022-07534-9 10.2471/BLT.18.228486 10.1016/s0091-7435(02)00058-0 10.1016/s2352-4642(20)30335-7 10.1016/s1473-3099(18)30783-7 10.1002/jia2.25343 10.1371/journal.pone.0230604 10.1136/bmjopen-2015-008552 10.1097/qai.0000000000000728 10.1016/s1473-3099(10)70092-x 10.1186/s12913-019-4351-3 10.1002/14651858.CD010385.pub2 10.11124/jbisrir-d-19-00381 10.1258/0956462981922034 10.1191/1478088706qp063oa 10.1007/s11135-017-0574-8 10.1111/j.1365-3156.2005.01473.x 10.1371/journal.pone.0127728 10.1016/j.ijgo.2015.04.013 10.4103/2224-3151.206690 10.1136/sextrans-2016-053062 10.1186/s12913-018-2935-y 10.1371/journal.pone.0198622 10.1371/journal.pone.0198698 10.1097/01.olq.0000251236.48770.35 10.1155/2013/247901 10.1016/j.ijgo.2015.04.015 10.1186/s12879-015-0868-1 10.1186/s12913-017-2325-x 10.1136/bmjopen-2017-020717 10.1097/QAI.0b013e318267bc94 10.1371/journal.pmed.1001233 10.1016/S0035-9203(98)91038-0 10.1016/j.ijgo.2015.04.009 10.1136/sti.79.3.208 10.1097/01.olq.0000245987.78067.0c 10.1155/2013/674584 10.1016/j.ijgo.2015.04.017 10.2471/blt.14.141879 10.1371/journal.pone.0135744 10.1093/heapol/czv116 10.1016/j.heliyon.2019.e01236 10.1371/journal.pone.0198784 10.1186/s12913-018-3844-9 10.1258/ijsa.2011.011139 10.1136/sti.76.3.203 10.1097/OLQ.0b013e3181bc0960 10.12688/gatesopenres.12768.1 10.1186/s12913-017-2494-7 10.1016/S2214-109X(19)30075-0 10.1177/0956462418800872 10.1371/journal.pone.0066905 10.4314/ahs.v15i2.8 10.1136/sextrans-2017-053491 10.1177/0956462419888315 10.1186/s12879-016-1573-4 10.1155/2016/1251238 10.1155/2018/3946862 10.1177/0956462416642340 10.1126/scitranslmed.aaa0056 10.1177/0956462418802685 10.1177/0956462414552696 10.1371/journal.pntd.0006360 10.1097/OLQ.0b013e318205e45d 10.1371/journal.pone.0052579 10.1136/sti.2006.023325 10.3855/jidc.2810 10.1136/sti.2009.038778 10.1371/journal.pone.0206204 10.1136/sti.2007.029462 10.1371/journal.pone.0124161 10.1177/0956462413507443 10.1007/s10461-018-2342-8 10.1590/1809-4503201400020005ENG 10.1007/s10461-019-02449-0 10.1590/S0102-311X2007001500013 10.1038/s41598-018-25941-4 10.1136/sextrans-2014-051625 10.1097/OLQ.0000000000000649 10.1186/s12913-015-1155-y 10.1186/s12913-018-3207-6 10.1371/journal.pone.0075327 10.1136/sti.78.4.282 10.1177/0956462418807112 10.1016/S1473-3099(18)30724-2 10.1371/journal.pone.0196209 10.1186/s12913-018-3154-2 10.1016/j.cmi.2018.08.001 10.1136/sti.2007.027060 10.1097/01.olq.0000245958.34961.27 10.1136/sti.2006.022566 10.1136/sti.2006.022475 10.1080/14737159.2021.1952074 10.1016/j.jadohealth.2016.03.014 10.1371/journal.pone.0124310 10.1016/s2214-109x(17)30263-2 10.1371/journal.pone.0229666 10.1371/journal.pone.0149568 10.1016/S2214-109X(20)30395-8 10.1186/s12879-021-06937-4 10.1080/14787210.2018.1463846 10.1093/cid/ciz603 10.1136/sextrans-2020-054911 10.1186/s12913-022-07557-7 10.1016/s0749-3797(01)00256-2 10.1097/01.AOG.0000157108.32059.8f
BMC Infectious Diseases; Martin K, Wenlock R et. al.

Jun 21st, 2022 - Sexually transmitted infections (STIs) in low- and middle-income countries (LMICs) are predominantly managed by syndromic management. However, most STIs are asymptomatic. These untreated STIs cause individual morbidity, and lead to high STI preval...

In vitro activity of amixicile against T. vaginalis from clinical isolates.
https://doi.org/10.1007/s00436-022-07567-8 10.1017/S0031182020001237 10.3389/froh.2021.752929 10.3390/antibiotics9050213 10.1128/AAC.03112-14 10.1128/AAC.00670-16 10.1517/14656566.2015.1035255 10.1128/AAC.00360-12
Parasitology Research; Jain E, Zaenker EI et. al.

Jun 9th, 2022 - Trichomoniasis is a sexually transmitted infection in humans caused by the protozoan Trichomonas vaginalis, the leading causative agent of vaginitis in women and urethritis in men worldwide. Metronidazole is the standard treatment for trichomonias...

Burden of trichomoniasis among older adults in the United States: a systematic review.
https://doi.org/10.1071/SH22009
Sexual Health; Lindrose AR, Htet KZ et. al.

Jun 7th, 2022 - Despite being one of the most common sexually transmitted infections (STIs) in the United States, the epidemiology of trichomoniasis remains understudied. One population that has been historically overlooked regarding STIs is that of older adults,...

Secnidazole: a treatment for trichomoniasis in adolescents and adults.
https://doi.org/10.1080/14787210.2022.2080656
Expert Review of Anti-infective Therapy; Muzny CA, Van Gerwen OT et. al.

Jun 2nd, 2022 - Single-dose 2-g oral secnidazole (SEC), newly approved by the U.S. Food and Drug administration (FDA) for treatment of trichomoniasis, is a potent 5-nitroimidazole with selective toxicity against various micro-organisms. It has been used internati...

see more →

Guidelines  3 results

Sexually transmitted diseases treatment guidelines, 2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885289
MMWR. Recommendations and Reports : Morbidity and Mortali... Workowski KA, Bolan GA et. al.

Jun 5th, 2015 - These guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs) were updated by CDC after consultation with a group of professionals knowledgeable in the field of STDs who met in Atlanta on April 30-M...

European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011.
https://doi.org/10.1258/ijsa.2011.011012
International Journal of STD & AIDS; Sherrard J, Donders G et. al.

Jul 29th, 2011 - Three common infections are associated with vaginal discharge: bacterial vaginosis, trichomoniasis and candidiasis, of which trichomoniasis is a sexually transmitted infection (STI). This guideline covers the presentation and clinical findings of ...

Guidelines for the laboratory diagnosis of trichomoniasis in East European countries.
https://doi.org/10.1111/j.1468-3083.2010.03601.x
Journal of the European Academy of Dermatology and Venere... Domeika M, Zhurauskaya L et. al.

Mar 20th, 2010 - The laboratory diagnosis of sexually transmitted infections in many Eastern European countries remains suboptimal. The main objective of the present evidence-based guidelines is to provide comprehensive information regarding the laboratory diagnos...

see more →

Drugs  134 results see all →

Clinicaltrials.gov  27 results

A Pilot Study to Evaluate the Efficacy and Safety of Lactobacillus Species Suppositories on Vaginal Health and pH
https://clinicaltrials.gov/ct2/show/NCT05060029

May 2nd, 2022 - The vaginal microbiome is said to be the first line of defence against vaginal infection, due to competitive exclusion and the destruction of pathogenic microbes. The vagina remains relatively sterile until a woman reaches puberty, after which the...

A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women
https://clinicaltrials.gov/ct2/show/NCT04758390

Nov 15th, 2021 - Reducing new HIV and STI infections among South African (SA) adolescent girls and young women (AGYW) is global public health priority. SA has the world's largest HIV epidemic, and SA AGYW acquire HIV at twice the rate of and seroconvert on average...

A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
https://clinicaltrials.gov/ct2/show/NCT03935217

Oct 1st, 2021 - The study will consist of a primary study phase (Visit 1 (baseline) to Visit 2 (Day 6-12)) and a follow-up phase (Visit 2 to Visit 3 (7-12 days post Visit 2)). During the primary phase patients will be randomly assigned in a 1:1 ratio to either So...

Clinical Investigation To Evaluate Cerviron Ovules® in Symptomatic Vaginitis
https://clinicaltrials.gov/ct2/show/NCT04735705

Sep 10th, 2021 - Vaginitis is the general term characterizing a spectrum of disorders of the vagina caused by infection, inflammation, or changes in the normal vaginal flora. Symptoms include abnormal vaginal discharge, odour, pruritus, pain, dysuria and/or discom...

Epidemiology of Abnormal Vaginal Discharge During Pregnancy
https://clinicaltrials.gov/ct2/show/NCT04719754

Jan 22nd, 2021 - Vaginitis among women of childbearing age is well acknowledged as a public health concern due to its high occurrence. Vulvovaginitis is a disorder of the vulva and/or vagina caused by infection, inflammation, or changes in the flora. There are man...

see more →

News  68 results

Will NAAT replace microscopy for the identification of organisms causing vaginitis?
https://www.mdedge.com/obgyn/article/252760/sexual-health/will-naat-replace-microscopy-identification-organisms-causing
Robert L. Barbieri, MD

Mar 15th, 2022 - Over the past 200 years, identification of the specific organism causing an infection has evolved from a reliance on patient history and physical examination to the use of microscopic examination of relevant biological samples to the rise of micro.

Treatment for BV, trichomoniasis approved for adolescents
https://www.mdedge.com/obgyn/article/251982/gynecology/treatment-bv-trichomoniasis-approved-adolescents
Jake Remaly

Feb 18th, 2022 - The Food and Drug Administration has approved secnidazole for the treatment of bacterial vaginosis (BV) and trichomoniasis in patients aged 12 years and older. The antimicrobial agent, marketed as Solosec, was first approved in 2017 as a treatment.

FDA Approves Secnidazole for BV, Trichomoniasis in Adolescents
https://www.medscape.com/viewarticle/968853

Feb 18th, 2022 - The Food and Drug Administration has approved secnidazole for the treatment of bacterial vaginosis (BV) and trichomoniasis in patients aged 12 years and older. The antimicrobial agent, marketed as Solosec, was first approved in 2017 as a treatment...

CDC Revamps STI Treatment Guidelines
https://www.medscape.com/viewarticle/955238

Jul 22nd, 2021 - The Centers for Disease Control and Prevention (CDC) today released updated sexually transmitted infection (STI) treatment guidelines to reflect current screening, testing, and treatment recommendations. The guidelines were last updated in 2015. D...

Secnidazole gets FDA nod for trichomoniasis
https://www.mdedge.com/infectiousdisease/article/242489/stis/secnidazole-gets-fda-nod-trichomoniasis
Heidi Splete

Jul 2nd, 2021 - The Food and Drug Administration has expanded the approval of secnidazole to include treatment of trichomoniasis in adults, according to a statement from manufacturer Lupin Pharmaceuticals. Trichomoniasis vaginalis is a common, nonviral, curable s.

see more →

Patient Education  7 results see all →